The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
| 1 | N | Nervous system | |
| 2 | N05 | Psycholeptics | |
| 3 | N05A | Antipsychotics | |
| 4 | N05AE | Indole derivatives | |
| 5 | N05AE04 | Ziprasidone |
The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. The DDD is a unit of measurement and does not necessarily reflect the recommended or Prescribed Daily Dose. Therapeutic doses for individual patients and patient groups will often differ from the DDD as they will be based on individual characteristics (such as age, weight, ethnic differences, type and severity of disease) and pharmacokinetic considerations.
| Route | Amount |
|---|---|
| ORAL - Oral | 80 mg |
| PAREN - Parenteral | 40 mg |
| Active Ingredient | Description | |
|---|---|---|
| Ziprasidone |
Ziprasidone has been shown to be an antagonist at both serotonin type 2A (5HT2A) and dopamine type 2 (D2) receptors. It is proposed that the therapeutic activity is mediated, in part, through this combination of antagonist activities. Ziprasidone is also a potent antagonist at 5HT2C and 5HT1D receptors, a potent agonist at the 5HT1A receptor and inhibits neuronal reuptake of norepinephrine and serotonin. |
| Title | Information Source | Document Type | |
|---|---|---|---|
| GEODON Capsule, hard | Health Products Regulatory Authority (IE) | MPI, EU: SmPC | |
| GEODON Powder for solution for injection | Web Search | MPI, EU: SmPC | |
| ZELDOX Capsule | Health Products and Food Branch (CA) | MPI, CA: SPM |
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.
